Table 1 Characteristics of studies examining the sensitivity and specificity of PSA in sub-Saharan Africa
Authors | Age* | Sensitivity < 4 4–10 > 10 | Specificity < 4 4–10 > 10 | Country | Patient symptoms/conditions | Event/Sample size | Design | ||||
|---|---|---|---|---|---|---|---|---|---|---|---|
Abdrabo et al. 2011[31] | 70.0 (6.75) | Na | 91.6 | Na | Na | 24.00 | Na | Sudan | Lower urinary tract symptoms | 36/118 | Pros |
Amayo and Obara, 2004 [29] | Nr | 89.8 | 83.7 | Na | 37.00 | 66.00 | Na | Kenya | Pre-surgery patients | 49/100 | Retro |
Heyns et al. 2001 [27] | 78.85 (9.32) | Na | 96.0 | Na | Na | 25.50 | Na | South Africa | Patients referred to tertiary hospital | ../3837 | Retro |
Manyahi et al. 2009 [32] | 73.00 (-) | Na | Na | 100.0 | Na | Na | Nr | Tanzania | Prostatism | 24/94 | Pros |
Mbaeri et al. 2018 [23] | 70.99 (9.1) | Na | 99.13 | 86.97 | Na | 2.15 | 25.84 | Nigeria | DRE suspicious of PCa | ../208 | Pros |
Niang et al. 2011 [30] | 65.50 (13.7) | 95.5 | Na | Nr | 4.50 | Na | 36.36 | Senegal | Population screening | 22/72 | Pros |
Nnabugwu et al. 2014 [18] | Na | Na | 96.3 | 85.2 | Na | 18.20 | 33.30 | Nigeria | Symptomatic prostate enlargement | 26/117 | Retro |
Ojewola et al. 2013 [24] | 67.9 (7.5) | Na | 91.9 | 75.7 | Na | 18.1 | 53.2 | Nigeria | Clinic evaluation for prostatic dx | 74/168 | Pros |
Oranusi et al. 2011 [25] | 70.00 (10.1) | nr | 99.2 | Na | nr | nr | nr | Nigeria | Patients diagnosed with PCa | 133/133 | Retro |
Tijani et al. 2017 [26] | 64.05 (6.75) | Na | 21.9 | Na | Na | 78.10 | Na | Nigeria | Abnormal DRE suggestive of PCa | 37/167 | Pros |